484 related articles for article (PubMed ID: 35390339)
21. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
Cella D; Motzer RJ; Suarez C; Blum SI; Ejzykowicz F; Hamilton M; Wallace JF; Simsek B; Zhang J; Ivanescu C; Apolo AB; Choueiri TK
Lancet Oncol; 2022 Feb; 23(2):292-303. PubMed ID: 35032437
[TBL] [Abstract][Full Text] [Related]
22. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ; Tannir NM; McDermott DF; Arén Frontera O; Melichar B; Choueiri TK; Plimack ER; Barthélémy P; Porta C; George S; Powles T; Donskov F; Neiman V; Kollmannsberger CK; Salman P; Gurney H; Hawkins R; Ravaud A; Grimm MO; Bracarda S; Barrios CH; Tomita Y; Castellano D; Rini BI; Chen AC; Mekan S; McHenry MB; Wind-Rotolo M; Doan J; Sharma P; Hammers HJ; Escudier B;
N Engl J Med; 2018 Apr; 378(14):1277-1290. PubMed ID: 29562145
[TBL] [Abstract][Full Text] [Related]
23. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
[TBL] [Abstract][Full Text] [Related]
24. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
Brown JE; Royle KL; Gregory W; Ralph C; Maraveyas A; Din O; Eisen T; Nathan P; Powles T; Griffiths R; Jones R; Vasudev N; Wheater M; Hamid A; Waddell T; McMenemin R; Patel P; Larkin J; Faust G; Martin A; Swain J; Bestall J; McCabe C; Meads D; Goh V; Min Wah T; Brown J; Hewison J; Selby P; Collinson F;
Lancet Oncol; 2023 Mar; 24(3):213-227. PubMed ID: 36796394
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Ascierto PA; Del Vecchio M; Mandalá M; Gogas H; Arance AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Márquez-Rodas I; Butler MO; Maio M; Middleton MR; de la Cruz-Merino L; Arenberger P; Atkinson V; Hill A; Fecher LA; Millward M; Khushalani NI; Queirolo P; Lobo M; de Pril V; Loffredo J; Larkin J; Weber J
Lancet Oncol; 2020 Nov; 21(11):1465-1477. PubMed ID: 32961119
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.
Amin A; Plimack ER; Ernstoff MS; Lewis LD; Bauer TM; McDermott DF; Carducci M; Kollmannsberger C; Rini BI; Heng DYC; Knox J; Voss MH; Spratlin J; Berghorn E; Yang L; Hammers HJ
J Immunother Cancer; 2018 Oct; 6(1):109. PubMed ID: 30348216
[TBL] [Abstract][Full Text] [Related]
28. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.
Kaseb AO; Hasanov E; Cao HST; Xiao L; Vauthey JN; Lee SS; Yavuz BG; Mohamed YI; Qayyum A; Jindal S; Duan F; Basu S; Yadav SS; Nicholas C; Sun JJ; Singh Raghav KP; Rashid A; Carter K; Chun YS; Tzeng CD; Sakamuri D; Xu L; Sun R; Cristini V; Beretta L; Yao JC; Wolff RA; Allison JP; Sharma P
Lancet Gastroenterol Hepatol; 2022 Mar; 7(3):208-218. PubMed ID: 35065057
[TBL] [Abstract][Full Text] [Related]
29. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Baas P; Scherpereel A; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Jahan T; Antonia S; Oulkhouir Y; Bautista Y; Cornelissen R; Greillier L; Grossi F; Kowalski D; Rodríguez-Cid J; Aanur P; Oukessou A; Baudelet C; Zalcman G
Lancet; 2021 Jan; 397(10272):375-386. PubMed ID: 33485464
[TBL] [Abstract][Full Text] [Related]
30. Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass).
Grünwald V; Ivanyi P; Zschäbitz S; Wirth M; Staib P; Schostak M; Dargatz P; Müller L; Metz M; Bergmann L; Steiner T; Welslau M; Lorch A; Rafiyan R; Hellmis E; Darr C; Schütt P; Meiler J; Kretz T; Loidl W; Flörcken A; Mänz M; Hinke A; Hartmann A; Grüllich C
Eur Urol; 2023 Dec; 84(6):571-578. PubMed ID: 37758574
[TBL] [Abstract][Full Text] [Related]
31. Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.
Choueiri TK; McDermott DF; Merchan J; Bauer TM; Figlin R; Heath EI; Michaelson MD; Arrowsmith E; D'Souza A; Zhao S; Roy A; Perini R; Vickery D; Tykodi SS
Lancet Oncol; 2023 May; 24(5):553-562. PubMed ID: 37011650
[TBL] [Abstract][Full Text] [Related]
32. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
[TBL] [Abstract][Full Text] [Related]
33. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Choueiri TK; Powles T; Burotto M; Escudier B; Bourlon MT; Zurawski B; Oyervides Juárez VM; Hsieh JJ; Basso U; Shah AY; Suárez C; Hamzaj A; Goh JC; Barrios C; Richardet M; Porta C; Kowalyszyn R; Feregrino JP; Żołnierek J; Pook D; Kessler ER; Tomita Y; Mizuno R; Bedke J; Zhang J; Maurer MA; Simsek B; Ejzykowicz F; Schwab GM; Apolo AB; Motzer RJ;
N Engl J Med; 2021 Mar; 384(9):829-841. PubMed ID: 33657295
[TBL] [Abstract][Full Text] [Related]
34. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
O'Hara MH; O'Reilly EM; Varadhachary G; Wolff RA; Wainberg ZA; Ko AH; Fisher G; Rahma O; Lyman JP; Cabanski CR; Mick R; Gherardini PF; Kitch LJ; Xu J; Samuel T; Karakunnel J; Fairchild J; Bucktrout S; LaVallee TM; Selinsky C; Till JE; Carpenter EL; Alanio C; Byrne KT; Chen RO; Trifan OC; Dugan U; Horak C; Hubbard-Lucey VM; Wherry EJ; Ibrahim R; Vonderheide RH
Lancet Oncol; 2021 Jan; 22(1):118-131. PubMed ID: 33387490
[TBL] [Abstract][Full Text] [Related]
35. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.
Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Olencki TE; Tarazi JC; Rosbrook B; Fernandez KC; Lechuga M; Choueiri TK
Lancet Oncol; 2018 Mar; 19(3):405-415. PubMed ID: 29439857
[TBL] [Abstract][Full Text] [Related]
36. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
[TBL] [Abstract][Full Text] [Related]
37. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K; Cho BC; Takahashi M; Okada M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Kodani M; Kitagawa Y
Lancet Oncol; 2019 Nov; 20(11):1506-1517. PubMed ID: 31582355
[TBL] [Abstract][Full Text] [Related]
38. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Janjigian YY; Shitara K; Moehler M; Garrido M; Salman P; Shen L; Wyrwicz L; Yamaguchi K; Skoczylas T; Campos Bragagnoli A; Liu T; Schenker M; Yanez P; Tehfe M; Kowalyszyn R; Karamouzis MV; Bruges R; Zander T; Pazo-Cid R; Hitre E; Feeney K; Cleary JM; Poulart V; Cullen D; Lei M; Xiao H; Kondo K; Li M; Ajani JA
Lancet; 2021 Jul; 398(10294):27-40. PubMed ID: 34102137
[TBL] [Abstract][Full Text] [Related]
39. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
Mir O; Cropet C; Toulmonde M; Cesne AL; Molimard M; Bompas E; Cassier P; Ray-Coquard I; Rios M; Adenis A; Italiano A; Bouché O; Chauzit E; Duffaud F; Bertucci F; Isambert N; Gautier J; Blay JY; Pérol D;
Lancet Oncol; 2016 May; 17(5):632-41. PubMed ID: 27068858
[TBL] [Abstract][Full Text] [Related]
40. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
